Drugs Made In America Acquisition II Signs $600M M&A Deal with Alpha AI Biotech Group
Drugs Made In America Acquisition II Corp. has delivered a preliminary proposal for a business combination with Alpha AI Biotech Group at a pre-money equity valuation of $600 million. The deal contemplates the issuance of 60 million shares at $10.00 each, plus up to 30 million earn-out shares based on post-closing stock performance. Additionally, the company received a $250,000 funding installment from Tal Alpha Yezum Vekidum Asakim (2003) Ltd. as part of a consolidated $700,000 convertible note facility.
- Value
- $600M
- Counterparty
- Alpha AI Biotech Group